论文部分内容阅读
近年来,脂质体作为一种新型眼用药物载体已经成为药剂学发展的一大研究热点。脂质体可以通过滴眼和眼内注射的方式给药治疗眼内疾病。同时,脂质体也可作为基因的载体对眼部进行基因治疗。与传统的剂型相比,脂质体在治疗眼部疾病方面具有明显的优势。尽管仍有很多问题有待解决,但脂质体在治疗眼部疾病方面的研究和应用必将日益广泛。现综合国内外的有关报道对脂质体作为药物载体在眼科中的应用进行了综述,为研究脂质体在眼科中的应用提供思路。
In recent years, liposomes as a new ophthalmic drug carrier has become a major research focus on the development of pharmaceutics. Liposomes can be administered by eye drops and intraocular injections to treat intraocular conditions. At the same time, liposomes can also act as a gene carrier for eye gene therapy. Liposomes have significant advantages in the treatment of eye diseases compared to traditional dosage forms. Although there are still many problems to be solved, the research and application of liposomes in the treatment of eye diseases are bound to be increasingly widespread. Now comprehensive domestic and foreign reports on the liposome as a drug carrier in the ophthalmology applications are reviewed for the study of liposomes in ophthalmology provide ideas.